Host molecular defense mechanisms against chlamydophila pneumoniae and genetic studies of immune-response-related genes in asthma

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 3, Issue 1, 2009, Pages 17-25

  Tamari, Mayumi ^a   Harada, Michishige ^a   Hirota, Tomomitsu ^a   Nakamura, Yusuke ^b  

^a INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Antibiotics; Asthma; Cardiovascular disease; Chlamydophila pneumoniae; Chronic obstructive pulmonary disease (COPD); Denetic polymorphisms; Glucocorticoids; Interferon ; Nod like receptors; Respiratory infections; Severity; Toll like receptors

Indexed keywords

AZITHROMYCIN; BECLOMETASONE; CD14 ANTIGEN; DEXAMETHASONE; GAMMA INTERFERON; GLUCOCORTICOID; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 18; LEVOFLOXACIN; NITRIC OXIDE SYNTHASE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; SIMVASTATIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TELITHROMYCIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

AGING; ANTIBIOTIC THERAPY; ASTHMA; CHLAMYDOPHILA INFECTION; CHLAMYDOPHILA PNEUMONIAE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HOST RESISTANCE; HUMAN; IMMUNOPATHOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ANIMAL; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; MICROBIOLOGY; PATENT; PATHOPHYSIOLOGY;

ANIMALS; ASTHMA; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; HUMANS; IMMUNITY, INNATE; PATENTS AS TOPIC; POLYMORPHISM, GENETIC;

EID: 61449196989     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221309787158380     Document Type: Review

References (114)

1. Holt PG, Macaubas C, Stumbles PA, Sly PD. The role of allergy in the development of asthma. Nature 1999; 402: B12-B17.
2. Cookson W. The immunogenetics of asthma and eczema: A new focus on the epithelium. Nat Rev Immunol 2004; 4: 978-988.
3. Hammad H, Lambrecht BN. Dendritic cells and epithelial cells: Linking innate and adaptive immunity in asthma. Nat Rev Immunol 2008; 8: 193-204.
4. Sutherland ER, Martin RJ. Asthma and atypical bacterial infection. Chest 2007; 132: 1962-1966.
5. Hammerschlag MR, Chirgwin K, Roblin PM, et al. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis 1992; 14: 178-182.
6. Martin RJ, Kraft M, Chu HW, Berns EA, Cassell GH. A link between chronic asthma and chronic infection. J Allergy Clin Immunol 2001; 107: 595-601.
7. Von Hertzen L, Toyryla M, Gimishanov A, et al. Asthma, atopy and Chlamydia pneumoniae antibodies in adults. Clin Exp Allergy 1999; 29: 522-528.
8. Black PN, Scicchitano R, Jenkins CR, et al. Serological evidence of infection with Chlamydia pneumoniae is related to the severity of asthma. Eur Respir J 2000; 15: 254-259.
9. Von HL, Vasankari T, Liippo K, Wahlstrom E, Puolakkainen M. Chlamydia pneumoniae and severity of asthma. Scand J Infect Dis 2002; 34: 22-27.
10. Wark PA, Johnston SL, Simpson JL, Hensley MJ, Gibson PG. Chlamydia pneumoniae immunoglobulin A reactivation and airway inflammation in acute asthma. Eur Respir J 2002; 20: 834-840.
11. Rottenberg ME, Gigliotti-Rothfuchs A, Wigzell H. The role of IFNgamma in the outcome of chlamydial infection. Curr Opin Immunol 2002; 14: 444-451.
12. Costa CP, Kirschning CJ, Busch D, et al. Role of chlamydial heat shock protein 60 in the stimulation of innate immune cells by Chlamydia pneumoniae. Eur J Immunol 2002; 32: 2460-2470.
13. Da Costa CU, Wantia N, Kirschning CJ, et al. Heat shock protein 60 from Chlamydia pneumoniae elicits an unusual set of inflammatory responses via Toll-like receptor 2 and 4 in vivo. Eur J Immunol 2004; 34: 2874-2884.
14. Joyee AG, Yang X. Role of toll-like receptors in immune responses to chlamydial infections. Curr Pharm Des 2008; 14: 593-600.
15. Kaiko GE, Phipps S, Hickey DK, et al. Chlamydia muridarum infection subverts dendritic cell function to promote Th2 immunity and airways hyperreactivity. J Immunol 2008; 180: 2225-3222.
16. Vercelli D. Discovering susceptibility genes for asthma and allergy. Nat Rev Immunol 2008; 8: 169-182.
17. Arroyo-Espliguero R, Avanzas P, Jeffery S, Kaski JC. CD14 and toll-like receptor 4: A link between infection and acute coronary events? Heart 2004; 90: 983-988.
18. Opitz B, Forster S, Hocke AC, et al. Nod1-mediated endothelial cell activation by Chlamydophila pneumoniae. Circ Res 2005; 96: 319-326.
19. Rottenberg ME, Gigliotti Rothfuchs A, Gigliotti D, et al. Regulation and role of IFN-gamma in the innate resistance to infection with Chlamydia pneumoniae. J Immunol 2000; 164: 4812-4818.
20. Belland RJ, Nelson DE, Virok D, et al. Transcriptome analysis of chlamydial growth during IFN-gamma-mediated persistence and reactivation. Proc Natl Acad Sci U S A 2003; 100: 15971-15976.
21. Molestina RE, Klein JB, Miller RD, Pierce WH, Ramirez JA, Summersgill JT. Proteomic analysis of differentially expressed Chlamydia pneumoniae genes during persistent infection of HEp-2 cells. Infect Immun 2002; 70: 2976-2981.
22. Yao SY, Ljunggren-Rose A, Stratton CW, Mitchell WM, Sriram S. Regulation by IFN-beta of inducible nitric oxide synthase and interleukin-12/p40 in murine macrophages cultured in the presence of Chlamydia pneumoniae antigens. J Interferon Cytokine Res 2001; 21: 137-146.
23. Varano B, Fantuzzi L, Puddu P, Borghi P, Belardelli F, Gessani S. Inhibition of the constitutive and induced IFN-beta production by IL-4 and IL-10 in murine peritoneal macrophages. Virology 2000; 277: 270-277.
24. Renauld JC. New insights into the role of cytokines in asthma. J Clin Pathol 2001; 54: 577-589.
25. Leonard C, Tormey V, Burke C, Poulter LW. Allergen-induced cytokine production in atopic disease and its relationship to disease severity. Am J Respir Cell Mol Biol 1997; 17: 368-375.
26. Smart JM, Horak E, Kemp AS, Robertson CF, Tang ML. Polyclonal and allergen-induced cytokine responses in adults with asthma: resolution of asthma is associated with normalization of IFNgamma responses. J Allergy Clin Immunol 2002; 110: 450-456.
27. Brooks GD, Buchta KA, Swenson CA, Gern JE, Busse WW. Rhinovirus-induced interferon-gamma and airway responsiveness in asthma. Am J Respir Crit Care Med 2003; 168: 1091-1094.
28. Wark PA, Johnston SL, Bucchieri F, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005; 201: 937-947.
29. Cippitelli M, Sica A, Viggiano V, et al. Negative transcriptional regulation of the interferon-gamma promoter by glucocorticoids and dominant negative mutants of c-Jun. J Biol Chem 1995; 270: 12548-12556.
30. Chan A, Newman DL, Shon AM, Schneider DH, Kuldanek S, Ober C. Variation in the type I interferon gene cluster on 9p21 influences susceptibility to asthma and atopy. Genes Immun 2006; 7: 169-178.
31. Lohoff M, Mak TW. Roles of interferon-regulatory factors in Thelper-cell differentiation. Nat Rev Immunol 2005; 5: 125-135.
32. Coccia EM, Stellacci E, Marziali G, Weiss G, Battistini A. IFNgamma and IL-4 differently regulate inducible NO synthase gene expression through IRF-1 modulation. Int Immunol 2000; 12: 977-985.
33. Nakao F, Ihara K, Kusuhara K, et al. Association of IFN-gamma and IFN regulatory factor 1 polymorphisms with childhood atopic asthma. J Allergy Clin Immunol 2001; 107: 499-504.
34. Kumar A, Ghosh B. A single nucleotide polymorphism (A -> G) in intron 3 of IFNgamma gene is associated with asthma. Genes Immun 2008; 9: 294-301.
35. Yang T, Stark P, Janik K, Wigzell H, Rottenberg ME. SOCS-1 protects against Chlamydia pneumoniae-induced lethal inflammation but hampers effective bacterial clearance. J Immunol 2008; 180: 4040-4049.
36. Harada M, Nakashima K, Hirota T, et al. Functional polymorphism in the suppressor of cytokine signaling 1 gene associated with adult asthma. Am J Respir Cell Mol Biol 2007; 36: 491-496.
37. Nathan C, Xie QW. Nitric oxide synthases: Roles, tolls, and controls. Cell 1994; 78: 915-918.
38. Liuba P, Pesonen E, Paakkari I, et al. Acute Chlamydia pneumoniae infection causes coronary endothelial dysfunction in pigs. Atherosclerosis 2003; 167: 215-222.
39. Holla LI, Stejskalova A, Znojil V, Vasku A. Analysis of the inducible nitric oxide synthase gene polymorphisms in Czech patients with atopic diseases. Clin Exp Allergy 2006; 36: 1592-1601.
40. Byrne GI, Ouellette SP, Wang Z, et al. Chlamydia pneumoniae expresses genes required for DNA replication but not cytokinesis during persistent infection of HEp-2 cells. Infect Immun 2001; 69: 5423-5429.
41. Naiki Y, Michelsen KS, Schroder NW, et al. MyD88 is pivotal for the early inflammatory response and subsequent bacterial clearance and survival in a mouse model of Chlamydia pneumoniae pneumonia. J Biol Chem 2005; 280: 29242-29249.
42. Netea MG, Kullberg BJ, Jacobs LE, et al. Chlamydia pneumoniae stimulates IFN-gamma synthesis through MyD88-dependent, TLR2- and TLR4-independent induction of IL-18 release. J Immunol 2004; 173: 1477-1482.
43. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001; 19: 423-474.
44. Hoshino T, Wiltrout RH, Young HA. IL-18 is a potent coinducer of IL-13 in NK and T cells: A new potential role for IL-18 in modulating the immune response. J Immunol 1999; 162: 5070-5077.
45. Yoshimoto T, Tsutsui H, Tominaga K, et al. IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad Sci U S A 1999; 96: 13962-13966.
46. Yoshimoto T, Mizutani H, Tsutsui H, et al. IL-18 induction of IgE: Dependence on CD4+ T cells, IL-4 and STAT6. Nat Immunol 2000; 1: 132-137.
47. Gohlke H, Illig T, Bahnweg M, et al. Association of the interleukin-1 receptor antagonist gene with asthma. Am J Respir Crit Care Med 2004; 169: 1217-1223.
48. Imboden M, Nicod L, Nieters A, et al. The common G-allele of interleukin-18 single-nucleotide polymorphism is a genetic risk factor for atopic asthma. The SAPALDIA Cohort Study. Clin Exp Allergy 2006; 36: 211-218.
49. Higa S, Hirano T, Mayumi M, et al. Association between interleukin-18 gene polymorphism 105A/C and asthma. Clin Exp Allergy 2003; 33: 1097-1102.
50. Shin HD, Kim LH, Park BL, et al. Association of interleukin 18 (IL18) polymorphisms with specific IgE levels to mite allergens among asthmatic patients. Allergy 2005; 60: 900-906.
51. de Graaf R, Kloppenburg G, Kitslaar PJ, Bruggeman CA, Stassen F. Human heat shock protein 60 stimulates vascular smooth muscle cell proliferation through Toll-like receptors 2 and 4. Microbes Infect 2006; 8: 1859-1865.
52. Kol A, Bourcier T, Lichtman AH, Libby P. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest 1999; 103: 571-577.
53. Kol A, Lichtman AH, Finberg RW, Libby P, Kurt-Jones EA. Cutting edge: Heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. J Immunol 2000; 164: 13-17.
54. Bulut Y, Faure E, Thomas L, et al. Chlamydial heat shock protein 60 activates macrophages and endothelial cells through Toll-like receptor 4 and MD2 in a MyD88-dependent pathway. J Immunol 2002; 168: 1435-1440.
55. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: Heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000; 164: 558-561.
56. Raby BA, Klimecki WT, Laprise C, et al. Polymorphisms in tolllike receptor 4 are not associated with asthma or atopy-related phenotypes. Am J Respir Crit Care Med 2002; 166: 1449-1456.
57. Werner M, Topp R, Wimmer K, et al. TLR4 gene variants modify endotoxin effects on asthma. J Allergy Clin Immunol 2003; 112: 323-330.
58. Fageras BM, Hmani-Aifa M, Lindstrom A, et al. A TLR4 polymorphism is associated with asthma and reduced lipopolysaccharide-induced interleukin-12(p70) responses in Swedish children. J Allergy Clin Immunol 2004; 114: 561-567.
59. Sackesen C, Karaaslan C, Keskin O, et al. The effect of polymorphisms at the CD14 promoter and the TLR4 gene on asthma phenotypes in Turkish children with asthma. Allergy 2005; 60: 1485-1492.
60. Ting JP, Willingham SB, Bergstralh DT. NLRs at the intersection of cell death and immunity. Nat Rev Immunol 2008; 8: 372-379.
61. Hysi P, Kabesch M, Moffatt MF, et al. NOD1 variation, immunoglobulin E and asthma. Hum Mol Genet 2005; 14: 935-941.
62. Weidinger S, Klopp N, Rummler L, et al. Association of NOD1 polymorphisms with atopic eczema and related phenotypes. J Allergy Clin Immunol 2005; 116: 177-184.
63. Eder W, Klimecki W, Yu L, et al. Association between exposure to farming, allergies and genetic variation in CARD4/NOD1. Allergy 2006; 61: 1117-1124.
64. Kabesch M, Peters W, Carr D, Leupold W, Weiland SK, von Mutius E. Association between polymorphisms in caspase recruitment domain containing protein 15 and allergy in two German populations. J Allergy Clin Immunol 2003; 111: 813-817.
65. Weidinger S, Klopp N, Rummler L, et al. Association of CARD15 polymorphisms with atopy-related traits in a population-based cohort of Caucasian adults. Clin Exp Allergy 2005; 35: 866-872.
66. Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992; 116: 273-278.
67. Maass M, Bartels C, Engel PM, Mamat U, Sievers HH. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 1998; 31: 827-832.
68. Fong IW, Chiu B, Viira E, Jang D, Mahony JB. de novo Induction of atherosclerosis by Chlamydia pneumoniae in a rabbit model. Infect Immun 1999; 67: 6048-6055.
69. Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J 2006; 27: 413-426.
70. Holgate ST, Holloway J, Wilson S, et al. Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities. J Allergy Clin Immunol 2006; 117: 496-506.
71. Howell JE, McAnulty RJ. TGF-beta: Its role in asthma and therapeutic potential. Curr Drug Targets 2006; 7: 547-565.
72. Cosentini R, Tarsia P, Canetta C, et al. Severe asthma exacerbation: role of acute Chlamydophila pneumoniae and Mycoplasma pneumoniae infection. Respir Res 2008; 9: 48.
73. Johnston SL, Blasi F, Black PN, Martin RJ, Farrell DJ, Nieman RB. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 2006; 354: 1589-600.
74. Hammerschlag MR, Sharma R. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections. Expert Opin Investig Drugs 2008; 17: 387-400.
75. Johnston SL, Martin RJ. Chlamydophila pneumoniae and Mycoplasma pneumoniae: A role in asthma pathogenesis? Am J Respir Crit Care Med 2005; 172: 1078-1089.
76. Meinke, A., Nagy, E., Winkler, B.: WO04113374 (2004).
77. Grandi, G., Ratti, G.: WO2005084306 (2005).
78. Bensi, G., Grandi, G.: US20050152926 (2005).
79. Meinke, A., Nagy, E., Winkler, B.: US20060240029 (2005).
80. Dautry-varsat, A., Subtil-sands, A.: US20070003568 (2005).
81. Mittelstadt PR, Ashwell JD. Inhibition of AP-1 by the glucocorticoid-inducible protein GILZ. J Biol Chem 2001; 276: 29603-29610.
82. Elenkov IJ. Glucocorticoids and the Th1/Th2 balance. Ann N Y Acad Sci 2004; 1024: 138-146.
83. Komura H, Matsushima H, Ouchi K, Shirai M, Nakazawa T, Furukawa S. Effects of antiasthma drugs on the growth of Chlamydophila pneumoniae in HEp-2 cells. J Infect Chemother 2003; 9: 160-164.
84. Laitinen K, Laurila AL, Leinonen M, Saikku P. Reactivation of Chlamydia pneumoniae infection in mice by cortisone treatment. Infect Immun 1996; 64: 1488-1490.
85. Caronzolo D, Lucini V, Pannacci M, et al. Glucocorticoids increase in vitro and in vivo activities of antibiotics against Chlamydophila pneumoniae. Antimicrob Agents Chemother 2004; 48: 4878-4881.
86. Eigen H, Reid JJ, Dahl R, et al. Evaluation of the addition of cromolyn sodium to bronchodilator maintenance therapy in the long-term management of asthma. J Allergy Clin Immunol 1987; 80: 612-621.
87. Shin HY, Kim JS, An NH, Park RK, Kim HM. Effect of disodium cromoglycate on mast cell-mediated immediate-type allergic reactions. Life Sci 2004; 74: 2877-2887.
88. Yamazaki T, Yamaguchi T, Sasaki N, Inoue M, Sato K, Kishimoto T. The inhibitory effect of disodium cromoglycate on the growth of Chlamydophila (Chlamydia) pneumoniae in vitro. Biol Pharm Bull 2006; 29: 799-800.
89. Kalvegren H, Andersson J, Grenegard M, Bengtsson T. Platelet activation triggered by Chlamydia pneumoniae is antagonized by 12-lipoxygenase inhibitors but not cyclooxygenase inhibitors. Eur J Pharmacol 2007; 566: 20-27.
90. Pitchford SC, Riffo-Vasquez Y, Sousa A, et al. Platelets are necessary for airway wall remodeling in a murine model of chronic allergic inflammation. Blood 2004; 103: 639-647.
91. Erkkila L, Jauhiainen M, Laitinen K, et al. Effect of simvastatin, an established lipid-lowering drug, on pulmonary Chlamydia pneumoniae infection in mice. Antimicrob Agents Chemother 2005; 49: 3959-3962.
92. Menzies D, Nair A, Meldrum KT, Fleming D, Barnes M, Lipworth BJ. Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma. J Allergy Clin Immunol 2007; 119: 328-335.
93. Donath B, Fischer C, Page S, et al. Chlamydia pneumoniae activates IKK/I kappa B-mediated signaling, which is inhibited by 4-HNE and following primary exposure. Atherosclerosis 2002; 165: 79-88.
94. Yoneda H, Miura K, Matsushima H, et al. Aspirin inhibits Chlamydia pneumoniae-induced NF-kappa B activation, cyclooxygenase-2 expression and prostaglandin E2 synthesis and attenuates chlamydial growth. J Med Microbiol 2003; 52: 409-415.
95. Li, E., Lad, S.: US20080124338 (2008).
96. Little CS, Bowe A, Lin R, et al. Age alterations in extent and severity of experimental intranasal infection with Chlamydophila pneumoniae in BALB/c mice. Infect Immun 2005; 73: 1723-1734.
97. Gutierrez F, Masia M, Mirete C, et al. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. J Infect 2006; 53: 166-174.
98. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008; 8: 183-192.
99. Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119: 405-413.
100. Cohen L, E X, Tarsi J, et al. Epithelial cell proliferation contributes to airway remodeling in severe asthma. Am J Respir Crit Care Med 2007; 176: 138-145.
101. Gencay MM, Tamm M, Glanville A, Perruchoud AP, Roth M. Chlamydia pneumoniae activates epithelial cell proliferation via NF-kappaB and the glucocorticoid receptor. Infect Immun 2003; 71: 5814-5822.
102. von HL. Role of persistent infection in the control and severity of asthma: Focus on Chlamydia pneumoniae. Eur Respir J 2002; 19: 546-556.
103. Leinonen M. Chlamydia pneumoniae and other risk factors for atherosclerosis. J Infect Dis 2000; 181 (Suppl 3): S414-416.
104. Miyashita N, Niki Y, Nakajima M, Kawane H, Matsushima T. Chlamydia pneumoniae infection in patients with diffuse panbronchiolitis and COPD. Chest 1998; 114: 969-971.
105. von Hertzen LC. Chlamydia pneumoniae and its role in chronic obstructive pulmonary disease. Ann Med 1998; 30: 27-37.
106. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993; 167: 841-849.
107. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-407.
108. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97: 633-636.
109. Taylor-Robinson D, Ong G, Thomas BJ, Rose ML, Yacoub MH. Chlamydia pneumoniae in vascular tissues from heart-transplant donors. Lancet 1998; 351: 1255-1256.
110. Rodel J, Woytas M, Groh A, et al. Production of basic fibroblast growth factor and interleukin 6 by human smooth muscle cells following infection with Chlamydia pneumoniae. Infect Immun 2000; 68: 3635-3641.
111. Hozawa A, Billings JL, Shahar E, Ohira T, Rosamond WD, Folsom AR. Lung function and ischemic stroke incidence: The Atherosclerosis Risk in Communities study. Chest 2006; 130: 1642-1649.
112. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension, and cardiovascular disease in chronic obstructive pulmonary disease. Eur Respir J 2008 (in press).
113. Branden E, Koyi H, Gnarpe J, Gnarpe H, Tornling G. Chronic Chlamydia pneumoniae infection is a risk factor for the development of COPD. Respir Med 2005; 99: 20-26.
114. Droemann D, Rupp J, Goldmann T, et al. Disparate innate immune responses to persistent and acute Chlamydia pneumoniae infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 791-797.